allogeneic variable delta 1 gamma-delta T cells

GDX012 is an investigational, allogeneic, non-engineered cell therapy composed of highly enriched variable delta 1 (Vδ1) gamma-delta (γδ) T cells derived from healthy donor blood. It is being developed for the treatment of certain cancers, primarily acute myeloid leukemia (AML), especially in patients with measurable residual disease after standard-of-care treatment. The therapy leverages the unique properties of Vδ1 γδ T cells, which can recognize and kill cancer cells through their specific receptors without requiring genetic engineering. These cells are expanded ex vivo to create an "off-the-shelf" product intended to provide anti-leukemic activity by targeting molecular patterns associated with cancer cell dysregulation. GDX012 has received FDA orphan drug designation for AML and is currently in phase I clinical trials to assess safety, tolerability, pharmacokinetics, and anti-leukemic efficacy[1][3][4][5][7].

Other names

allogeneic enriched variable delta 1 gamma delta T-cellsallogeneic Vδ1+ γδ T cells